Page 18 - Acasti Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acasti pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acasti Pharma Today - Breaking & Trending Today

Acasti Pharma Announces Annual Grants of Performance Stock

LAVAL, Québec, June 22, 2022 (GLOBE NEWSWIRE) Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage,. ....

United States , Robert Blum , Jan Dalvise , Exchange Commission , Acasti Pharma Inc , Company Nasdaq , Lytham Partners , Securities Exchange , Regulation Services Provider , Stock Option Plan , Orphan Drug Designation , Subarachnoid Hemorrhage , Postherpetic Neuralgia , Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Tsx Venture Exchange Acst , Acasti Pharma ,

Acasti Pharma (ACST) Scheduled to Post Earnings on Tuesday

Acasti Pharma (NASDAQ:ACST – Get Rating) is set to release its earnings data before the market opens on Tuesday, June 21st. Analysts expect Acasti Pharma to post earnings of ($0.13) per share for the quarter. NASDAQ:ACST traded up $0.02 on Friday, reaching $0.92. The stock had a trading volume of 1,200 shares, compared to its […] ....

United States , Acasti Pharma , Morgan Stanley , Acasti Pharma Inc , Citadel Advisors , Renaissance Technologies , America Corp , Get Rating , Jane Street Group , Pharma Inc , Nasdaq Acst ,

Brokerages Expect Acasti Pharma Inc. (NASDAQ:ACST) to Announce -$0.13 EPS

Analysts expect Acasti Pharma Inc. (NASDAQ:ACST – Get Rating) to announce earnings of ($0.13) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Acasti Pharma’s earnings. Acasti Pharma reported earnings per share of ($0.24) in the same quarter last year, which suggests a positive year-over-year growth rate of […] ....

United States , Acasti Pharma , Morgan Stanley , Acasti Pharma Company Profile Get Rating , Zacks Investment Research , America Corp , Acasti Pharma Inc , Sigma Securities , Citadel Advisors , Get Rating , Investment Research , Street Group , Pharma Company Profile , Pharma Inc , Nasdaq Acst ,

Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

/PRNewswire/ Acasti Pharma Inc. (Nasdaq: ACST and TSX-V: ACST) ("Acasti"; the "Company"), a late-stage specialty pharmaceutical company with drug delivery. ....

United States , Robert Blum , Acasti Pharma , Jan Dalvise , Acasti Pharma Inc , Partner Of Lytham Partners , Lytham Partners , Venture Exchange , Lytham Partners Investor Conference , Subarachnoid Hemorrhage , New Drug Application , Managing Partner , Lytham Partners Summer , Orphan Drug Designation , Postherpetic Neuralgia , Acasti Pharma Inc ,

Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

/PRNewswire/ Acasti Pharma Inc. (Nasdaq: ACST and TSX-V: ACST) ("Acasti"; the "Company"), a late-stage specialty pharmaceutical company with drug delivery. ....

United States , Robert Blum , Acasti Pharma , Jan Dalvise , Acasti Pharma Inc , Partner Of Lytham Partners , Lytham Partners , Venture Exchange , Lytham Partners Investor Conference , Subarachnoid Hemorrhage , New Drug Application , Managing Partner , Lytham Partners Summer , Orphan Drug Designation , Postherpetic Neuralgia ,